Cases & Deals

  • Home
  • Practices
  • Resonant Therapeutics enters into strategic alliance with Retrogenix to identify targets of anti-tumor antibodies

Share

Resonant Therapeutics enters into strategic alliance with Retrogenix to identify targets of anti-tumor antibodies

January 2020

Client(s) Resonant Therapeutics, Inc.

Jones Day represented Resonant Therapeutics, Inc. in a strategic alliance with Retrogenix to identify the targets of Resonant antibodies directed against the tumor microenvironment. The collaboration exploits Resonant's proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult-to-treat tumors.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.